HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Dare Bioscience (NASDAQ:DARE) and maintained a $7 price target.
July 13, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Dare Bioscience and maintained a $7 price target.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Dare Bioscience. The maintained price target of $7 indicates the firm's continued confidence in the company's potential. This could potentially lead to increased investor confidence and a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100